CBio Limited
is an Australian company with a global focus. With a vision to improve patient lives, CBio is focused on developing new generation products for the treatment of autoimmune and inflammatory diseases.

CBio’s business goal is to become a pre-eminent early stage developer of clinical therapeutics. To achieve this, CBio will continue to develop and protect its current technologies, leverage its technology platform to in-license and develop new therapeutic candidates, and complete commercial partnerships at the optimal stage of development. Crucially, CBio will continue to engage and strengthen partnerships with research and education institutions to identify and harness breakthrough research and technologies.


Announcement: Commencement of dosing in Phase IIa study
18 June 2008

Shareholder Newsletter
11 June 2008

Information Release: CBio announces commencement of Phase IIa clinical trial in rheumatoid arthritis
28 May 2008

Disclosure Announcement: CBio signs agreement with Novo Nordisk
27 May 2008

Information Release - Cpn10: Evidence of Utility Beyond a Single Indication
20 May 2008




Subscribe to email alerts